内布拉斯加大学医学中心和阿南达宣布，FDA批准了一项治疗创伤后应激障碍(PTSD)的研究性新药的临床试验

2022-05-18 网络网络

国际文传电讯社

企业/

该研究将评估一种研究性药物Nantheia™ ATL5的有效性，其成分包含采用了阿南达专有递送技术的大麻二酚。

内布拉斯加大学医学中心(UNMC)和阿南达医药科技公司(ANANDA Scientific Inc )宣布合作进行一项新的临床试验，研究成人创伤后应激障碍(PTSD)的治疗。

该试验由首席研究员Mathew Rizzo, M.D.领导。他是UNMC神经科学系的 Reynolds荣誉教授和系主任以及Nebraska Medicine的神经学服务的首席医生。

该研究将评估一种研究性药物Nantheia™ ATL5的有效性，其成分包含采用了阿南达专有递送技术的大麻二酚。该试验的研究性新药(IND)申请已获得美国食品药品管理局(FDA)的批准。

（Clinical Trials.gov识别编号：NCT05269459）

阿南达首席执行官Sohail R. Zaidi表示：“这是我们针对创伤后应激障碍的第二次临床试验。我们很荣幸与UNMC的研究团队合作，针对这种使人衰弱的病情评估我们的潜力药物。这是我们为创伤后应激障碍患者提供潜在改善型治疗方案的重要一步。”

Rizzo博士表示：“我们研究团队的一个关键目标就是推进新疗法的循证研究，从而为大量创伤后应激障碍患者提供创新治疗方案。我们很高兴能与阿南达合作开展这项试验。”

Rizzo博士也是美国国立卫生研究院大平原IDeA临床和转化研究网络的主任。他同时是American Brain Coalition执行委员会的主席。该联盟倡导推进神经系统治疗的研究。

Rizzo博士的研究团队将包括认知神经科学家、UNMC神经科学系副教授Jennifer Merickel博士以及UNMC精神病学系高级执业注册护士、临床医生和研究员Brigette Vaughan。

这项II期双盲、安慰剂对照、随机临床研究计划招募240名受试者，对Nantheia™ ATL5的有效性和安全性进行严格的临床和现实世界评估。

关于 NANTHEIA™ ATL5

Nantheia™ ATL5是一种研究性药物，其成分包含利用阿南达专有Liquid Structure技术递送的大麻二酚。临床前和初步临床研究表明，阿南达的Liquid Structure™递送技术（从以色列耶路撒冷的Lyotropic Delivery Systems (LDS) Ltd获得许可）可以提高大麻二酚的有效性和稳定性。Nantheia™ ATL5是一种口服产品，每粒软胶囊含有100毫克大麻二酚。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1839971, encodeId=945618399e172, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 02 11:29:59 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221150, encodeId=14c5122115019, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 20 12:27:11 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335396, encodeId=1e14133539606, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 09:29:59 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445380, encodeId=4662144538078, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri May 20 09:29:59 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
2023-03-02 bugit

#FDA批准#

59 0
[GetPortalCommentsPageByObjectIdResponse(id=1839971, encodeId=945618399e172, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 02 11:29:59 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221150, encodeId=14c5122115019, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 20 12:27:11 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335396, encodeId=1e14133539606, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 09:29:59 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445380, encodeId=4662144538078, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri May 20 09:29:59 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
2022-05-20 1209e435m98(暂无昵称)

学习了，谢谢分享

60 0
[GetPortalCommentsPageByObjectIdResponse(id=1839971, encodeId=945618399e172, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 02 11:29:59 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221150, encodeId=14c5122115019, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 20 12:27:11 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335396, encodeId=1e14133539606, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 09:29:59 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445380, encodeId=4662144538078, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri May 20 09:29:59 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
2022-05-20 智者为医08

#创伤#

54 0
[GetPortalCommentsPageByObjectIdResponse(id=1839971, encodeId=945618399e172, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu Mar 02 11:29:59 CST 2023, time=2023-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221150, encodeId=14c5122115019, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri May 20 12:27:11 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335396, encodeId=1e14133539606, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 09:29:59 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445380, encodeId=4662144538078, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Fri May 20 09:29:59 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
2022-05-20 ms1260584454294838

#应激#

0 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

报道

内布拉斯加大学医学中心和阿南达宣布，FDA批准了一项治疗创伤后应激障碍(PTSD)的研究性新药的临床试验

相关资讯

拓展阅读

科室

工具

服务